^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    allogeneic K562-GM tumor cell vaccine

    i
    Associations
    News

    Trials

    Company:
    National Cancer Institute
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma (NCT00487305)
    Phase 1
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    11/07/2023
    Initiation :
    06/01/2007
    Primary completion :
    07/01/2023
    Completion :
    10/01/2024
    CSF2
    |
    allogeneic K562-GM tumor cell vaccine
    Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia (NCT00301093)
    Phase 1
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    10/28/2020
    Initiation :
    09/01/2005
    Primary completion :
    05/01/2007
    Completion :
    09/10/2020
    ABL1 • BCR
    |
    imatinib • allogeneic K562-GM tumor cell vaccine
    Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation (NCT00809250)
    Phase 1
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    09/16/2020
    Initiation :
    11/01/2008
    Primary completion :
    05/01/2011
    Completion :
    01/01/2020
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    allogeneic K562-GM tumor cell vaccine
    Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI (NCT00363649)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Completed
    Last update posted :
    11/13/2018
    Initiation :
    09/01/2006
    Primary completion :
    09/01/2017
    Completion :
    09/01/2017
    ABL1 • BCR
    |
    imatinib • Leukine (sargramostim) • allogeneic K562-GM tumor cell vaccine
    Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor (NCT00694330)
    Phase 1
    Massachusetts General Hospital
    Completed
    Last update posted :
    06/22/2017
    Initiation :
    06/01/2008
    Primary completion :
    08/01/2009
    Completion :
    08/01/2009
    CSF2
    |
    allogeneic K562-GM tumor cell vaccine